Stanford’s lysosome protein degradation spinout Lycia emerged with $50m of capital from Versant Ventures to develop a portfolio of drug candidates.
Lycia Therapeutics, a US-based protein degradation drug development spinout of Stanford University, exited stealth on Tuesday with $50m from founding investor Versant Ventures.
Lycia Therapeutics has built a drug discovery platform for creating lysosome targeting chimeras (Lytacs) capable of degrading cell-surface proteins ordinarily inaccessible with traditional therapeutic methods, combatting intractable diseases including certain subtypes of cancer.
Lytacs consist of an antibody bound to the ligands of peptides known as glycopeptides, in which amino acids have glycan molecules covalently…
